ADR (SMQ) Interacting drug Ω (Ω 0.025)a Ω (Ω 0.025)a Ω (Ω 0.025)a
Total Pre-Covid Post-Covid
TdP/QTpb azithromycin 3.00 (2.41) -0.04 (-10.37) 1.67 (1.08)
ceftriaxone 1.10 (0.20) -0.11 (-10.43) 0.07 (-0.84)
lopinavir+ritonavir 2.48 (1.85) 0.00 (-10.32) 0.72 (0.09)
tocilizumab 0.72 (-0.49) -0.12 (-10.44) -0.12 (-1.33)
Cardiomyopathy azithromycin -0.78 (-3.37) -0.12 (-10.45) -0.35 (-2.94)
ceftriaxone -2.67 (-12.99) -0.19 (-10.51) -2.44 (-12.76)
lopinavir+ritonavir -1.55 (-5.33) 0.00 (-10.32) -1.36 (-5.14)
tocilizumab -2.20 (-12.53) -0.42 (-10.75) -1.84 (-12.16)
Drug related hepatic disorders - severe events only azithromycin 2.08 (1.68) -0.21 (-10.54) 0.91 (0.52)
ceftriaxone 0.66 (0.14) -0.77 (-11.09) -0.17 (-0.70)
lopinavir+ritonavir -1.33 (-2.20) 0.00 (-10.32) -2.42 (-3.29)
tocilizumab 1.89 (1.36) -0.41 (-10.73) 0.80 (0.26)
Dyslipidaemia azithromycin 1.88 (0.47) -0.01 (-10.34) 0.67 (-0.74)
ceftriaxone 2.38 (0.96) -0.02 (-10.34) 0.93 (-0.48)
lopinavir+ ritonavir 1.02 (-0.12) 0.00 (-10.32) 2.83 (1.69)
tocilizumab -0.82 (-4.61) -0.24 (-10.56) -1.26 (-5.05)